Summary
What do they do? OnPoint NYC provides supervised overdose-prevention spaces in East Harlem and Washington Heights. Its wellness hubs offer low-barrier clinical care, harm-reduction supplies and case management. Participants can also access meals, hygiene services and connections to treatment and other support.
Why we’re interested in this organization:
Immediate trained monitoring can stabilize acute overdoses while creating access to continuing care.
Integrated clinical, wound-care and basic-needs services reach people disconnected from traditional care.
Low-barrier access and case management can relieve daily resource constraints and support treatment engagement.
Our main reservations:
Additional overdose lethality, repeat-recipient distribution and donor capacity remain unresolved.
Household consumption amounts and baseline resources are conditional priors; activity counts and claimed taxpayer savings do not measure household gains.
Fresh original tax-return access was blocked; expense totals are corroborated from IRS-derived extraction, with inherited reconciliation dated distinctly.
What do you get for your dollar? $2.9M per DALY in New York City. DALY is our one-year comparison unit. QALY-based health gains and income-welfare equivalents retain their original assumptions; they are not measured clinical DALYs. Conditional whole-recipient recognized expense per MSA-resident combined welfare-equivalent healthy years. Health QALYs separate; household amounts unmeasured, taxpayer savings excluded, cash/full-resource perimeter unresolved..
Reported intervention events -> unique-person annual hazard difference -> finite discounted survival difference, not intervention events equated with deaths. Household service availability is evidence of possible pathways, not measured consumption gains.
1. What do they do?
OnPoint NYC formed from New York Harm Reduction Educators and Washington Heights Corner Project in 2022. This report uses On Point NYC Inc., EIN 20-8672015, and its entire reported resource envelope. It includes overdose prevention, clinical and mental-health care, syringe services, outreach and basic-needs support. The current service page explicitly includes Bronx outreach alongside the two Manhattan centers. Families or predecessor names do not receive separate overlapping credit. History Services
The ordinary donation route does not promise an exclusive OPC purchase. The model therefore retains all recipient costs and quantifies only a clinically meaningful overdose-survival component. Donate
2. Monitoring and information sharing
The third-year report covers November 30,2023 to November 29,2024, despite its 2025 navigation label. It lists 434 purported fatal overdoses prevented; this review treats these as reported intervention events, not independently demonstrated deaths averted. The model assumes that annual event scale remains a usable planning anchor with FY 2025 costs; a cumulative 2,000-event milestone in May 2026 is not annualized. Third-year report Current milestone
The original first-two-month evaluation distinguishes naloxone, oxygen, monitoring and stimulant-related supportive interventions, and has no untreated comparison group. These categories have different untreated lethality. Ask for distinct intervention recipients, repeat events, severity, alternative rescue, out-of-site deaths and longitudinal survival. Initial evaluation
The newly retrieved original PDF locates enrollment/utilization on printed pages 14–15, wraparound 16–17, buprenorphine 18, wound care 19, interventions 22–24 and EMS 30–31. Activity counts do not establish counterfactual treatment success. Unique OPC users are not unique overdose-intervention recipients. The PDF's EMS percentage is per OPC visit, unlike the website highlight's intervention denominator. Original report
3. Qualitative assessment
A Vancouver model estimated 8.4–50.9 potentially averted deaths among 1,004 recorded overdose events, depending strongly on assumed community nonfatal overdose incidence. Of those events, 453 met its potentially fatal definition, based on naloxone, emergency calling or ambulance use. The 8.4–50.9 estimate is modeled deaths across the 1,004-event program, not measured deaths or the fatality rate of its 453 severe events. That historical, pre-fentanyl model is context for our 2% untreated-lethality judgment, not a modern New York causal rate. A further 50% transfer/alternative-rescue factor reflects contemporary community naloxone, emergency response and differences in severity. Original mortality model
A later Vancouver cohort found lower adjusted all-cause mortality among frequent users, but residual confounding and nonrandom selection limit causal transfer. Ontario's controlled interrupted time-series did not identify a statistically significant aggregate mortality improvement. Neither result warrants assigning all city overdose trends to OnPoint. Local difference-in-differences crime research provides reassurance against a simple crime-increase claim, not QALYs or proof that every possible adverse effect is absent. Cohort Ontario study NYC crime study
Alternative access includes city naloxone, drug checking and vending machines, and SSPs such as Housing Works, Harlem United, VOCAL and Alliance for Positive Change. These establish that alternative services exist, not that any particular participant receives them. Clinical, infection, wound care, treatment, warmth/respite and mental-health pathways remain unpriced pending attributable health coefficients; no overlapping mortality award is added. Possible precipitated withdrawal, delayed emergency escalation, increased risky consumption or displacement, and participant cash/time burdens remain unresolved. Ontario's aggregate null cannot establish zero individual benefit; population dilution and possible slowing of mortality increase matter. Alternative access
4. What do you get for your dollar?
The beta conditional reference keeps the alpha health assumptions and adds an explicitly hypothetical signed household consumption branch: 4.20 health QALYs plus 1.30 income-equivalent healthy years equals 5.505 welfare-equivalent healthy years. At $16,203,740 annual recognized expense, cost is about $2.9M per DALY. Health-only remains $3.9M per DALY. The Coefficient Giving-inspired log crosswalk is a welfare comparison, not measured clinical QALYs or an observed OnPoint return.
The 434 annual intervention events are assigned to 217 distinct people by judgment, or two events each. A 2% lethal-risk input and 50% contemporary transfer factor imply a 0.02 annual hazard reduction during one funded year. Counterfactual mortality hazard is 0.08 and intervention hazard 0.06 during that year. Both groups subsequently face 0.08, so later overdose and competing mortality erode the survival difference. We integrate their survival difference for at most ten years at utility 0.7 and a 3% discount rate. Each person has one survival trajectory: repeated rescue cannot create multiple lifetime awards.
Only 25% of this proportional continuation-scale benefit is attributed to an ordinary gift after public support, reserves and replacement donors; that is an explicit funding-response prior, not an observed budget elasticity. A 98% MSA-resident share is also judgment, acknowledging nonlocal users without assuming city-site location proves residency. The boundary is the official 22-county MSA, not the wider CSA.
Broad alternatives change severity, unique-person clustering, funding response, competing mortality and horizon. Zero and harmful outcomes remain possible. A 10% extra-resource stress tests unrecognized volunteer and partner resources; it is not a measured add-on. Recognized donated medication is already in the financial envelope and is not added twice. Future medical spending and broader social opportunity costs are unpriced.
Household reference: two disjoint common-alive cohorts, 100 additional households gaining $300 annual net purchasing power and 100 other households bearing $30 annual net cash burden, at $10,000 baseline annual household consumption/resources. All last one year, with 98% MSA allocation and 3% discounting. The gain count assumes 400 eligible exposures times 25% donor response, a prior not calibrated from activity counts. These are expected common-alive household person-year exposures, excluding income obtained only because someone survives. For a household with both gains and costs, net them before applying the log; the two modeled cohorts are disjoint. No earnings multiplier, extra-survivor consumption credit or positive-overlap haircut is used.
Food/hygiene services can release purchasing power when they replace paid purchases, but replacing another free provider releases none. Benefits case management can increase resources, but no verified net awards, household baseline or persistence was found, so earnings and benefit awards remain unpriced. Beneficiary gains are net of their own cash burdens; the disjoint burden-only cohort includes households with no gain. The positive gain and negative burden stay unchanged at clinical null. A separate complete funding-replacement case has no additional service exposure and no induced burden. Negative losses have full causal and independent weight.
Taxpayer EMS savings are neither household consumption nor returned donor cash. The PDF's $13 million claim applies an assumed $30,000 per avoided emergency response, not a measured counterfactual saving; no savings are subtracted from the cost envelope.10% additional partner-resource stress adds cost. Cash-only operating expense and participant-time opportunity cost remain unknown. Alpha health low/high alternatives remain intact in the embedded historical diagnostic. New clinical-null, financial-only, adverse, unknown, burden-only, delay, consumption and residence cases are conditional sensitivity cases, not confidence bounds.
Independent share=1 is a conditional structural choice because the health branch values only finite survival and does not also assign mental-health or stability utility. Common-alive basic-needs households are a service cohort, not selected rescue survivors. No measured absence of overlap is claimed. Low/high donor-response cases jointly scale clinical capacity and household exposure to 10%/50%; per-exposed-household negative cash loss retains full weight. Clinical-null switches lethality only, preserving service exposure and signed consumption.
Model, assumptions and sensitivity
Whole merged recipient annual recognized cost; overdose-survival component only. Unpriced clinical, infection, psychosocial and public effects prevent a whole-portfolio claim. Household signed consumption is separately in the welfare denominator; editionQalys is health-only.
g=.98 is a subjective share of modeled unique participants who reside in the official22-county MSA. All sites/known outreach are within the MSA but residence records were unavailable.
d=ln(1.03); delta=(E/U)*l*a; lambda1=m-delta>=0; F(k,t)=(1-exp(-k*t))/k. H=U*u*[F(lambda1+d,1)-F(m+d,1)+(exp(-lambda1)-exp(-m))*exp(-d)*F(m+d,T-1)]; Qall=b*H-h; QNYC=g*Qall; Price10=10*C/QNYC if positive. The event-level risk input is converted to an annual hazard decrement by the explicit linear approximation delta=(E/U)*l*a, not asserted to be an exact probability-to-hazard identity.; I=.5*sum_j[N_j*g_j*sum_t((1+r)^(-delay-t))*ln(1+netConsumptionChange_j/baselineConsumption_j)]; W=editionQalys+I. Every net change is household-specific before log; disjoint cohorts only.
- E
- 434 reported interventions per historical year (observed). 434 intervention claim in a specified historical 12-month report, transferred to current planning by judgment. [year3]
- U
- 217 distinct intervention recipients assumed (judgment). Explicit uncalibrated modeling prior; no claim this is measured OnPoint evidence. [initial] [public26]
- l
- 0.02 fraction as formula defines (judgment). 2% is judgment informed by an old model's 8.4–50.9/1004 range, not modern observed lethality. [fatalityModel]
- a
- 0.5 fraction as formula defines (judgment). Explicit uncalibrated modeling prior; no claim this is measured OnPoint evidence. [initial] [public26]
- b
- 0.25 fraction as formula defines (judgment). Explicit uncalibrated modeling prior; no claim this is measured OnPoint evidence. [initial] [public26]
- m
- 0.08 annual all-cause hazard (judgment). Explicit uncalibrated modeling prior; no claim this is measured OnPoint evidence. [initial] [public26]
- u
- 0.7 fraction as formula defines (judgment). Explicit uncalibrated modeling prior; no claim this is measured OnPoint evidence. [initial] [public26]
- T
- 10 maximum follow-up years (judgment). Explicit uncalibrated modeling prior; no claim this is measured OnPoint evidence. [initial] [public26]
- g
- 0.98 fraction as formula defines (judgment). Explicit uncalibrated modeling prior; no claim this is measured OnPoint evidence. [initial] [public26]
- C
- 16203740 USD annual recipient cost (observed). FY2025 original Form 990 and Schedule D reconciled in the September 14 alpha primary-source checks; October 5 IRS-derived extraction corroborates the total, but fresh original access was blocked. [return2025] [schedule2025]
- h
- 0.00 all-population QALYs lost (judgment). Explicit uncalibrated modeling prior; no claim this is measured OnPoint evidence. [initial] [public26]
- AdditionalGainHouseholds
- 100 expected household-year exposure (judgment). 400 eligible incremental common-alive exposures times 25% funding response; distinct from burden-only cohort. [services] [caseManagement] [public26] [alternatives] [cg]
- NetGain
- 300 USD per household-year (judgment). Net replacement of paid consumption after alternative free provision and own costs; conditional prior. [services] [caseManagement] [public26] [alternatives] [cg]
- BurdenOnlyHouseholds
- 100 expected household-year exposure (judgment). Disjoint households with net cash loss and no gain; full actual causal weight. [services] [caseManagement] [public26] [alternatives] [cg]
- NetBurden
- -30 USD per household-year (judgment). Travel, phone or documentation cash costs independent of clinical effect; full weight. [services] [caseManagement] [public26] [alternatives] [cg]
- BaselineConsumption
- 10000 USD annual household resources (judgment). Positive cash plus in-kind baseline; not measured OnPoint household resources. [services] [caseManagement] [public26] [alternatives] [cg]
- IncomeDuration
- 1 year (judgment). Finite common-alive exposure; excludes automatic extra-survivor income. [services] [caseManagement] [public26] [alternatives] [cg]
- IncomeOverlap
- 1 fraction (judgment). No unsupported positive-overlap or success haircut. [services] [caseManagement] [public26] [alternatives] [cg]
Conditional survival and net consumption reference: Cost: $16.2M; New York City health QALYs: 4.20; all-population health QALYs: 4.29. Income-equivalent healthy years: 1.30. {"E": 434,"U": 217,"l": 0.02,"a": 0.5,"b": 0.25,"m": 0.08,"u": 0.7,"T": 10,"g": 0.98,"C": 16203740,"h": 0,"delay": 0,"r": 0.03}; Two disjoint cohorts: 100 additional common-alive households gain $300 annual consumption net of their own costs; 100 other households incur $30 net cost with no gain, baseline $10,000; one year only. Gains and burdens persist under clinical null. These are uncalibrated welfare priors. Co-occurring gain and costs must be netted within a household before log conversion.
No additional clinical effect; financial pathways persist: Cost: $16.2M; New York City health QALYs: 0.00; all-population health QALYs: 0.00. Income-equivalent healthy years: 1.30. {"E": 434,"U": 217,"l": 0,"a": 0.5,"b": 0.25,"m": 0.08,"u": 0.7,"T": 10,"g": 0.98,"C": 16203740,"h": 0,"delay": 0,"r": 0.03};
Clinical null with no purchasing-power gain and full burdens: Cost: $16.2M; New York City health QALYs: 0.00; all-population health QALYs: 0.00. Income-equivalent healthy years: -0.15. {"E": 434,"U": 217,"l": 0,"a": 0.5,"b": 0.25,"m": 0.08,"u": 0.7,"T": 10,"g": 0.98,"C": 16203740,"h": 0,"delay": 0,"r": 0.03};
No additional program capacity and no induced burden: Cost: $16.2M; New York City health QALYs: 0.00; all-population health QALYs: 0.00. Income-equivalent healthy years: 0.00. {"E": 434,"U": 217,"l": 0.02,"a": 0.5,"b": 0,"m": 0.08,"u": 0.7,"T": 10,"g": 0.98,"C": 16203740,"h": 0,"delay": 0,"r": 0.03};
Clinical harm plus household losses: Cost: $16.2M; New York City health QALYs: -0.24; all-population health QALYs: -0.25. Income-equivalent healthy years: -1.49. {"E": 434,"U": 217,"l": 0,"a": 0.5,"b": 0.25,"m": 0.08,"u": 0.7,"T": 10,"g": 0.98,"C": 16203740,"h": 0.25,"delay": 0,"r": 0.03};
Unresolved net household consumption: Cost: $16.2M; New York City health QALYs: 4.20; all-population health QALYs: 4.29. {"E": 434,"U": 217,"l": 0.02,"a": 0.5,"b": 0.25,"m": 0.08,"u": 0.7,"T": 10,"g": 0.98,"C": 16203740,"h": 0,"delay": 0,"r": 0.03}; Missing household cash data cannot establish zero income effect.
No consumption gain; burden remains: Cost: $16.2M; New York City health QALYs: 4.20; all-population health QALYs: 4.29. Income-equivalent healthy years: -0.15. {"E": 434,"U": 217,"l": 0.02,"a": 0.5,"b": 0.25,"m": 0.08,"u": 0.7,"T": 10,"g": 0.98,"C": 16203740,"h": 0,"delay": 0,"r": 0.03};
10% unrecognized partner-resource stress: Cost: $17.8M; New York City health QALYs: 4.20; all-population health QALYs: 4.29. Income-equivalent healthy years: 1.30. {"E": 434,"U": 217,"l": 0.02,"a": 0.5,"b": 0.25,"m": 0.08,"u": 0.7,"T": 10,"g": 0.98,"C": 17824114,"h": 0,"delay": 0,"r": 0.03};
Two-year delayed incremental service capacity: Cost: $16.2M; New York City health QALYs: 3.96; all-population health QALYs: 4.04. Income-equivalent healthy years: 1.22. {"E": 434,"U": 217,"l": 0.02,"a": 0.5,"b": 0.25,"m": 0.08,"u": 0.7,"T": 10,"g": 0.98,"C": 16203740,"h": 0,"delay": 2,"r": 0.03};
Conditional larger purchasing-power benefit: Cost: $16.2M; New York City health QALYs: 4.20; all-population health QALYs: 4.29. Income-equivalent healthy years: 21.56. {"E": 434,"U": 217,"l": 0.02,"a": 0.5,"b": 0.25,"m": 0.08,"u": 0.7,"T": 10,"g": 0.98,"C": 16203740,"h": 0,"delay": 0,"r": 0.03};
Replacement free services eliminate gain; higher cash burden: Cost: $16.2M; New York City health QALYs: 4.20; all-population health QALYs: 4.29. Income-equivalent healthy years: -1.49. {"E": 434,"U": 217,"l": 0.02,"a": 0.5,"b": 0.25,"m": 0.08,"u": 0.7,"T": 10,"g": 0.98,"C": 16203740,"h": 0,"delay": 0,"r": 0.03};
80% resident allocation: Cost: $16.2M; New York City health QALYs: 3.43; all-population health QALYs: 4.29. Income-equivalent healthy years: 1.06. {"E": 434,"U": 217,"l": 0.02,"a": 0.5,"b": 0.25,"m": 0.08,"u": 0.7,"T": 10,"g": 0.8,"C": 16203740,"h": 0,"delay": 0,"r": 0.03};
10% ordinary-gift capacity response: Cost: $16.2M; New York City health QALYs: 1.68; all-population health QALYs: 1.72. Income-equivalent healthy years: 0.52. {"E": 434,"U": 217,"l": 0.02,"a": 0.5,"b": 0.1,"m": 0.08,"u": 0.7,"T": 10,"g": 0.98,"C": 16203740,"h": 0,"delay": 0,"r": 0.03}; Clinical and financial additional service exposure scale jointly: 400 eligible gain exposures times 10%=40; burden-only exposure 40. Cash loss per actually exposed household has full weight; no clinical-success haircut.
50% ordinary-gift capacity response: Cost: $16.2M; New York City health QALYs: 8.41; all-population health QALYs: 8.58. Income-equivalent healthy years: 2.60. {"E": 434,"U": 217,"l": 0.02,"a": 0.5,"b": 0.5,"m": 0.08,"u": 0.7,"T": 10,"g": 0.98,"C": 16203740,"h": 0,"delay": 0,"r": 0.03}; Clinical and financial additional service exposure scale jointly: 400 eligible gain exposures times 50%=200; burden-only exposure 200. Cash loss per actually exposed household has full weight; no clinical-success haircut.
Counterfactual: Public grants, opioid settlement support, ordinary community naloxone/EMS and existing staffing continue. The intervention changes one year's mortality hazard, not all subsequent risk; equal post-year-one hazards impose recurrence and competing mortality.
Attribution: l is a historical-context-informed lethality prior, a a contemporary transfer/rescue factor, b financial additionality. No separate lives-saved multiplier, rescue-lifetime sum, or additional portfolio mortality claim.
Weak-confidence partial-health best estimate. The event count is observed as an organizational claim; causal lethality, unique-person count, hazards, utility and gift response are subjective. The adverse case prevents interpreting omissions as a proven benefit floor. Net consumption amounts and common-alive exposure are uncalibrated conditional priors; unknown scenario remains unknown.
Sensitivity
- No additional clinical effect; financial pathways persist (combined welfare): $12.5M per DALY. {"E": 434,"U": 217,"l": 0,"a": 0.5,"b": 0.25,"m": 0.08,"u": 0.7,"T": 10,"g": 0.98,"C": 16203740,"h": 0,"delay": 0,"r": 0.03}; ; price is combined welfare; health-only diagnostic is priceper DALY.
- Clinical null with no purchasing-power gain and full burdens (combined welfare): no finite positive estimate. {"E": 434,"U": 217,"l": 0,"a": 0.5,"b": 0.25,"m": 0.08,"u": 0.7,"T": 10,"g": 0.98,"C": 16203740,"h": 0,"delay": 0,"r": 0.03}; ; price is combined welfare; health-only diagnostic is priceper DALY.
- No additional program capacity and no induced burden (combined welfare): no finite positive estimate. {"E": 434,"U": 217,"l": 0.02,"a": 0.5,"b": 0,"m": 0.08,"u": 0.7,"T": 10,"g": 0.98,"C": 16203740,"h": 0,"delay": 0,"r": 0.03}; ; price is combined welfare; health-only diagnostic is priceper DALY.
- Clinical harm plus household losses (combined welfare): no finite positive estimate. {"E": 434,"U": 217,"l": 0,"a": 0.5,"b": 0.25,"m": 0.08,"u": 0.7,"T": 10,"g": 0.98,"C": 16203740,"h": 0.25,"delay": 0,"r": 0.03}; ; price is combined welfare; health-only diagnostic is priceper DALY.
- Unresolved net household consumption (combined welfare): no finite positive estimate. {"E": 434,"U": 217,"l": 0.02,"a": 0.5,"b": 0.25,"m": 0.08,"u": 0.7,"T": 10,"g": 0.98,"C": 16203740,"h": 0,"delay": 0,"r": 0.03}; Missing household cash data cannot establish zero income effect.; price is combined welfare; health-only diagnostic is priceper DALY.
- No consumption gain; burden remains (combined welfare): $4.0M per DALY. {"E": 434,"U": 217,"l": 0.02,"a": 0.5,"b": 0.25,"m": 0.08,"u": 0.7,"T": 10,"g": 0.98,"C": 16203740,"h": 0,"delay": 0,"r": 0.03}; ; price is combined welfare; health-only diagnostic is priceper DALY.
- 10% unrecognized partner-resource stress (combined welfare): $3.2M per DALY. {"E": 434,"U": 217,"l": 0.02,"a": 0.5,"b": 0.25,"m": 0.08,"u": 0.7,"T": 10,"g": 0.98,"C": 17824114,"h": 0,"delay": 0,"r": 0.03}; ; price is combined welfare; health-only diagnostic is priceper DALY.
- Two-year delayed incremental service capacity (combined welfare): $3.1M per DALY. {"E": 434,"U": 217,"l": 0.02,"a": 0.5,"b": 0.25,"m": 0.08,"u": 0.7,"T": 10,"g": 0.98,"C": 16203740,"h": 0,"delay": 2,"r": 0.03}; ; price is combined welfare; health-only diagnostic is priceper DALY.
- Conditional larger purchasing-power benefit (combined welfare): $629K per DALY. {"E": 434,"U": 217,"l": 0.02,"a": 0.5,"b": 0.25,"m": 0.08,"u": 0.7,"T": 10,"g": 0.98,"C": 16203740,"h": 0,"delay": 0,"r": 0.03}; ; price is combined welfare; health-only diagnostic is priceper DALY.
- Replacement free services eliminate gain; higher cash burden (combined welfare): $6.0M per DALY. {"E": 434,"U": 217,"l": 0.02,"a": 0.5,"b": 0.25,"m": 0.08,"u": 0.7,"T": 10,"g": 0.98,"C": 16203740,"h": 0,"delay": 0,"r": 0.03}; ; price is combined welfare; health-only diagnostic is priceper DALY.
- 80% resident allocation (combined welfare): $3.6M per DALY. {"E": 434,"U": 217,"l": 0.02,"a": 0.5,"b": 0.25,"m": 0.08,"u": 0.7,"T": 10,"g": 0.8,"C": 16203740,"h": 0,"delay": 0,"r": 0.03}; ; price is combined welfare; health-only diagnostic is priceper DALY.
- 10% ordinary-gift capacity response (combined welfare): $7.4M per DALY. {"E": 434,"U": 217,"l": 0.02,"a": 0.5,"b": 0.1,"m": 0.08,"u": 0.7,"T": 10,"g": 0.98,"C": 16203740,"h": 0,"delay": 0,"r": 0.03}; Clinical and financial additional service exposure scale jointly: 400 eligible gain exposures times 10%=40; burden-only exposure 40. Cash loss per actually exposed household has full weight; no clinical-success haircut.; price is combined welfare; health-only diagnostic is priceper DALY.
- 50% ordinary-gift capacity response (combined welfare): $1.5M per DALY. {"E": 434,"U": 217,"l": 0.02,"a": 0.5,"b": 0.5,"m": 0.08,"u": 0.7,"T": 10,"g": 0.98,"C": 16203740,"h": 0,"delay": 0,"r": 0.03}; Clinical and financial additional service exposure scale jointly: 400 eligible gain exposures times 50%=200; burden-only exposure 200. Cash loss per actually exposed household has full weight; no clinical-success haircut.; price is combined welfare; health-only diagnostic is priceper DALY.
Unresolved inputs
- Distinct intervention recipients and repeated-event severity, with alternative rescue evidence.
- Current donation-sensitive capacity beyond public appropriations and other donors.
- Longitudinal mortality, health utility and MSA residency.
- Comparable FY2023 merger perimeter and unpriced non-overdose benefits or harms.
- Household baseline consumption, net purchasing-power gains/losses versus alternative free provision, common-alive exposure and residency.
- Fresh original FY2025 reconciliation, cash/inventory matching, volunteer, outside care and participant-time resources.
Health and income breakdown
For the modeled $16.2M: 4.20 health QALYs + 1.30 income-equivalent healthy years in New York City: $2.9M per DALY. Income equivalents are welfare comparisons, not observed QALYs or DALYs.
5. Funding and previous grants
Original June-ending accrual returns and Schedule D reconciliations report $11,980,572 in FY 2023, $15,432,498 in FY 2024 and $16,203,740 in FY 2025. The FY 2023 amended return supersedes its earlier filing and explicitly aligns with completed audited statements. The three returns report no separately netted fundraising, gaming or inventory expense, and no donated-service addback in Schedule D. FY 2025 Schedule M reports $336,016 in donated drugs/medical supplies, already recognized as property rather than an additional service addback. We flag FY 2023 as noncomparable pending confirmation of the exact merger-period perimeter rather than display an artificial three-year mean. FY 2025 return [FY 2023 amendment](https://projects.propublica.org/nonprofits/full_text/202423619349300202/IRS990 ScheduleO)
FY 2025 revenue was $19,268,609, including $18,181,362 government grants, and ending net assets were $18,520,698; cash was $6,815,648 and grants receivable $9,424,280. Net assets are not all spendable cash. Current city reporting explicitly funds sustained/expanded wraparound hours and services and names OnPoint in infrastructure investments. An ordinary donor cannot receive credit for all these appropriated services. Current settlement report
The official financial directory still emphasizes older documents, so this review uses more recent original IRS filings. No verified current unfunded opening or dollar-specific capacity promise was assumed. Financial directory
Expense appendix: FY 2025 Form 990 functional costs are $14,411,565 program services, $1,664,638 management/general and $127,537 fundraising, totaling $16,203,740. The earlier amended original amount is retained, but no comparable three-year average is accepted until the merger-period perimeter is resolved.
October 5 beta verification: the IRS-derived directory still identifies On Point NYC Inc., EIN 20-8672015, and corroborates FY 2025 expense $16,203,740, revenue $19,268,609 and net assets $18,520,698. Original Form 990, schedules and XML returned security blocks. Detailed government grants, cash, receivable, functional expenses and donated-property reconciliation above remain inherited from the September 14 alpha primary checks, not freshly reverified. Own financial directory still links 2022 WHCP and 2020–21 audits. Current extraction
Recognized accrual cost is a starting full-recipient resource envelope, not measured cash outlay. The $336,016 noncash-property value cannot simply be subtracted to establish cash expense without inventory and expense matching. Volunteer services, outside clinical resources and participant time could increase total cost; only the explicit 10% resource case prices omitted partner resources. FY 26 city quarterly participants overlap, so they are not summed into unique annual reach. Unfunded hours, incremental staffing and ordinary-gift response remain unverified.
Annual expenses
Organization-level spending, including programs, administration and fundraising. The research list averages three comparable, consecutive full fiscal years when available.
- FY 2023: $12.0M; On Point NYC Inc., EIN 20-8672015, 12-month period, June-ending accrual recognized recipient expense; no reported event/COGS or donated-service reconciliation addback.. Source
- FY 2024: $15.4M; On Point NYC Inc., EIN 20-8672015, 12-month period, June-ending accrual recognized recipient expense; no reported event/COGS or donated-service reconciliation addback.. Source
- FY 2025: $16.2M; On Point NYC Inc., EIN 20-8672015, 12-month period, June-ending accrual recognized recipient expense; no reported event/COGS or donated-service reconciliation addback.. Source
6. Sources
- FY2023 original Form 990. On Point NYC / IRS. Published: not stated; retrieved: 2026-09-14.
- FY2023 original Schedule D. On Point NYC / IRS. Published: not stated; retrieved: 2026-09-14.
- FY2024 original Form 990. On Point NYC / IRS. Published: not stated; retrieved: 2026-09-14.
- FY2024 original Schedule D. On Point NYC / IRS. Published: not stated; retrieved: 2026-09-14.
- FY2025 original Form 990. On Point NYC / IRS. Published: not stated; retrieved: 2026-09-14.
- FY2025 original Schedule D. On Point NYC / IRS. Published: not stated; retrieved: 2026-09-14.
- FY2025 original noncash property schedule. On Point NYC / IRS. Published: not stated; retrieved: 2026-09-14.
- FY2023 amendment explanation. On Point NYC / IRS. Published: not stated; retrieved: 2026-09-14.
- Merger and recipient history. OnPoint NYC. Published: not stated; retrieved: 2026-09-14.
- Current service portfolio and locations. OnPoint NYC. Published: not stated; retrieved: 2026-09-14.
- Third-year operations, November 2023–November 2024. OnPoint NYC. Published: not stated; retrieved: 2026-09-14.
- 2,000 cumulative interventions milestone. OnPoint NYC. Published: 2026-05-06; retrieved: 2026-09-14.
- Funding and original-document directory. OnPoint NYC. Published: not stated; retrieved: 2026-09-14.
- Current opioid settlement expenditure and service report. NYC Department of Health and Mental Hygiene. Published: not stated; retrieved: 2026-09-14.
- First two months of OPC operation, uncontrolled quality-improvement study. Harocopos et al., JAMA Network Open. Published: not stated; retrieved: 2026-09-14.
- Vancouver model of potentially avoided overdose deaths. Milloy et al., PLOS ONE. Published: 2008-10-07; retrieved: 2026-09-14.
- Frequent facility use and all-cause mortality cohort. Kennedy et al., PLOS Medicine. Published: 2019-11-26; retrieved: 2026-09-14.
- Controlled interrupted time-series of Ontario SCS mortality. Study authors, indexed by PubMed. Published: not stated; retrieved: 2026-09-14.
- Difference-in-differences neighborhood crime study. Chalfin et al., JAMA Network Open. Published: not stated; retrieved: 2026-09-14.
- Ordinary donation route. OnPoint NYC. Published: not stated; retrieved: 2026-09-14.
- Original third-year impact report. OnPoint NYC. Published: not stated; retrieved: 2026-10-05.
- Income benefits and housing case management. OnPoint NYC. Published: not stated; retrieved: 2026-10-05.
- Alternative naloxone and drug checking access. NYC Health. Published: not stated; retrieved: 2026-10-05.
- Logarithmic income and healthy-year comparison. Coefficient Giving. Published: not stated; retrieved: 2026-10-05.
- FY2025 IRS-derived extraction and filing directory. ProPublica / IRS. Published: not stated; retrieved: 2026-10-05.